Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was $53.12 for the day, up 0.91% from the previous closing price of $52.64. In other words, the price has increased by $0.91 from its previous closing price. On the day, 0.56 million shares were traded. CRNX stock price reached its highest trading level at $54.27 during the session, while it also had its lowest trading level at $52.5.
Ratios:
Our analysis of CRNX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 17.72 and its Current Ratio is at 17.72. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 06, 2024, initiated with a Buy rating and assigned the stock a target price of $68.
On January 16, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $50.
On December 21, 2023, Jefferies started tracking the stock assigning a Hold rating and target price of $35.Jefferies initiated its Hold rating on December 21, 2023, with a $35 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 25 ’24 when Wilson Marc sold 19,056 shares for $53.88 per share. The transaction valued at 1,026,737 led to the insider holds 111,092 shares of the business.
Betz Stephen F. sold 3,000 shares of CRNX for $160,290 on Jul 25 ’24. The Chief Scientific Officer now owns 75,611 shares after completing the transaction at $53.43 per share. On Jul 15 ’24, another insider, Knight Jeff E., who serves as the Chief Operating Officer of the company, sold 27,000 shares for $55.00 each. As a result, the insider received 1,485,000 and left with 51,653 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 4320398336 and an Enterprise Value of 3302707712. Its current Enterprise Value per Revenue stands at 1673.104 whereas that against EBITDA is -13.378.
Stock Price History:
Over the past 52 weeks, CRNX has reached a high of $55.78, while it has fallen to a 52-week low of $15.76. The 50-Day Moving Average of the stock is 9.91%, while the 200-Day Moving Average is calculated to be 31.35%.
Shares Statistics:
CRNX traded an average of 950.04K shares per day over the past three months and 609820 shares per day over the past ten days. A total of 78.86M shares are outstanding, with a floating share count of 73.56M. Insiders hold about 6.72% of the company’s shares, while institutions hold 99.06% stake in the company. Shares short for CRNX as of 1721001600 were 6579559 with a Short Ratio of 6.93, compared to 1718323200 on 5862862. Therefore, it implies a Short% of Shares Outstanding of 6579559 and a Short% of Float of 8.520000399999999.
